BiotechTube
Home/Pipeline/CXCL12 Formulation for DFU

CXCL12 Formulation for DFU

Diabetic Foot Ulcers

Pre-clinicalActive

Key Facts

Indication
Diabetic Foot Ulcers
Phase
Pre-clinical
Status
Active
Company
ViCapsys

About ViCapsys

ViCapsys is a private, pre-revenue biotech leveraging a platform based on the cytokine CXCL12 to locally modulate immune and inflammatory responses. Its lead program aims to enable long-term survival of transplanted pancreatic islet cells to cure Type 1 Diabetes, with supporting data from non-human primate studies. The company is also developing non-cellular applications for diabetic foot ulcers and abdominal adhesions, building on intellectual property licensed from Massachusetts General Hospital.

View full company profile

Therapeutic Areas

Type 1 DiabetesDiabetic Foot UlcersAbdominal Adhesions

Other Diabetic Foot Ulcers Drugs

DrugCompanyPhase
PEP Biologic™Intent BiologicsUnknown
TOP-N53Topadur PharmaPhase 2
IonoJet™OriginPhase 3
FGF-1Zhittya Genesis MedicinePhase 2
CYP-006Cynata TherapeuticsPreclinical
NovoSorb BTMPolyNovoClinical Investigation
EPIFIX® / AMNIOFIX®MiMedx GroupPost-Market Study
DermagraftOrganogenesisApproved/Commercial